washingtonexaminer.com

washingtonexaminer.com
Share

washingtonexaminer.com

 •  February 13

A top Food and Drug Administration official said Tuesday the reauthorization of the agency's animal drug user fee agreements would help speed up its process of approving generic animal drugs, decreasing the cost of caring for food-producing and companion animals. "The current reauthorization significantly reduces timeframes for getting these...

washingtonexaminer.com

 •  February 7

The House voted Tuesday to loosen Obamacare rules that require restaurant chains, supermarkets and convenience stores to make calorie counts and other nutrition information available to customers. Under the Common Sense Nutrition Disclosure Act, introduced by Rep. Cathy McMorris Rodgers, R-Wash., food retailers would no longer need to provide...

washingtonexaminer.com

 •  February 6

The White House is making a major push for a House vote soon on a bill that would let terminally ill patients try experimental drugs. President Trump called for Congress to pass "right to try" legislation in his first State of the Union address last week as well as at the Republicans' retreat afterward. The endorsement comes as Vice President Mike...

washingtonexaminer.com

 •  February 6

Supporters of a bill to let terminally ill patients bypass the Food and Drug Administration to get access to experimental treatments are pressing for a House vote quickly. Reps. Andy Biggs, R-Ariz., and Brian Fitzpatrick, R-Pa., wrote a letter signed by 40 lawmakers to House GOP leadership requesting a vote as soon as possible on the bill. The...

washingtonexaminer.com

 •  February 2

President Trump urged Congress on Thursday to approve a bill that lets terminally ill patients try experimental treatments, saying that it will give patients the “hope of finding something.” Trump has made an open push for Congress to approve "right to try" legislation since calling for passage during his first State of the Union speech on Tuesday....

washingtonexaminer.com

 •  January 9

Alex Azar, President Trump’s pick to lead Health and Human Services, said that no company has ever lowered a price for a brand name drug because the current system doesn’t incentivize it. Azar is a former CEO of the U.S. division for drugmaker Eli Lilly and withstood questioning from Democrats during his confirmation hearing before the Senate...

washingtonexaminer.com

 •  December 12, 2017

Several Republican senators joined Democrats in calling for reining in a tool that drugmakers use to extend their monopolies. Republicans and Democrats bashed the technique, called “evergreening,” during a hearing Tuesday on high drug prices in the Senate Health, Education, Labor and Pensions Committee. Evergreening involves a drugmaker making...

washingtonexaminer.com

 •  November 15, 2017

STEUBENVILLE — It was hard to find a sign supporting Issue 2 in this Eastern Ohio river town before the election. But residents received more than their share of direct mail pieces, robocalls, and an avalanche of ads about the controversial ballot question that no one can dispute went down in flames. In fact, Issue 2 suffered the largest loss of...

washingtonexaminer.com

 •  October 9, 2017

Democratic California Gov. Jerry Brown is expected to sign a bill into law Monday that would require drug companies to justify planned price hikes to their medications. Under the bill, drug companies would need to notify private health insurers and the state government health plan, known as Medi-Cal, of their intentions 60 days before the price...

washingtonexaminer.com

 •  September 29, 2017

A federal judge on Friday refused to block a Maryland law aimed at expensive generic drug pricing from going into effect. The dismissal is a blow to the Association for Accessible Medicines, which represents generics and initiated the lawsuit. The organization said it was reviewing the decision. U.S. District Judge Marvin Garbis denied the...